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Abstract: Manipulation of the immune response is a game changer in lung cancer treatment,
revolutionizing management. PD1 and CTLA4 are dynamically expressed on different T cell subsets
that can either disrupt or sustain tumor growth. Monoclonal antibodies (MoAbs) against PD1/PDL1
and CTLA4 have shown that inhibitory signals can be impaired, blocking T cell activation and function.
MoAbs, used as both single-agents or in combination with standard therapy for the treatment of
advanced non-small cell lung cancer (NSCLC), have exhibited advantages in terms of overall survival
and response rate; nivolumab, pembrolizumab, atezolizumab and more recently, durvalumab, have
already been approved for lung cancer treatment and more compounds are in the pipeline. A better
understanding of signaling elicited by these antibodies on T cell subsets, as well as identification
of biological determinants of sensitivity, resistance and correlates of efficacy, will help to define the
mechanisms of antitumor responses. In addition, the relevance of T regulatory cells (Treg) involved in
immune responses in cancer is attracting increasing interest. A major challenge for future research is
to understand why a durable response to immune checkpoint inhibitors (ICIs) occurs only in subsets
of patients and the mechanisms of resistance after an initial response. This review will explore current
understanding and future direction of research on ICI treatment in lung cancer and the impact of
tumor immune microenvironment n influencing clinical responses.
Keywords: lung cancer; immune checkpoint inhibitors; tumor microenvironment; immune evasion;
Treg; nivolumab; pembrolizumab; atezolizumab; durvalumab
1. Introduction
Immunotherapy has marked a revolution in the treatment of lung cancer. By manipulating the
immune response to target tumour cells, disease control is achievable in subsets of lung cancer patients,
resulting in prolonged survival, although resistance after the initial response is not uncommon.
Scientific interest is now directed to understanding the mechanisms of response to immune
checkpoint inhibitors (ICIs) and determining prognostic factors and biomarkers.
Immune checkpoints, physiologically, are involved in preventing T cells from turning against
healthy tissue through inhibitory and stimulatory pathways. To evade the immune response, cancer
cells may develop the ability to exploit those pathways, impairing specific T cell activation that may
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lead to the mounting of a specific anticancer response [1]. Major targets for approved pharmacological
interventions are the surface molecules PD-1 (programmed cell death protein-1) and CTLA-4 (cytotoxic
T-lymphocyte associated antigen-4). Additional targets, including LAG-3, TIM-3, TIGIT, VISTA,
B7/H3, OX40, ICOS, GITR, 4-1BB and CD40, are potential candidates for the development of new
therapeutic options.
The cell-surface receptor PD-1 is expressed by T cells on activation during priming or expansion
and binds to one of two ligands, PD-L1 or PD-L2. Many cell types can express PD-L1, including
tumor cells and immune cells after exposure to cytokines, such as interferon (IFN)-γ; however, PD-L2
is expressed mainly on dendritic cells in normal tissues [2]. It must be considered that PD1 and
CTLA4 can be expressed in a dynamic fashion on different T cell subsets; therefore, an approach
aiming to tailor a precise therapy should be undertaken, characterizing the phenotypic expressions
of those molecules on T cells in different patients. Binding of PD-L1 or PD-L2 to PD-1 generates
an inhibitory signal that attenuates the activity of T cells. When inactivation of T cells occurs through
such mechanisms, cancer cells evade attack. Immune checkpoint inhibitors (ICIs) have been developed
to target those self-tolerance pathways that are exploited by tumors to escape immune recognition and
destruction (Figure 1). Monoclonal antibodies (MoAbs) against PD1/PDL1 and CTLA4 have shown
that inhibitory signals can be impaired blocking T cell activation and function. Among ICIs, nivolumab
and pembrolizumab target the checkpoint protein PD-1, whereas atezolizumab and durvalumab target
PDL1, all approved by FDA for treatment of lung cancer patients. Ipilimumab targets CTLA-4 and is
awaiting approval for lung cancer treatment [3–5]. Beyond the expression of PD-L1, other biomarkers
are under investigation to better stratify patients who may benefit from immune-checkpoint inhibitors
(ICIs) (Table 1). One of these is represented by human leukocyte antigen class I (HLA-I). Homozygosity
in at least one HLA-I locus (“A,” “B” or “C”) has been associated with a reduction of overall survival
after treatment with ICIs [6]. Another promising biomarker is LAG-3, which has showed a synergy
with PD-1 in different cancer types [7]. Conversely, STK11/LKB1 inactivation represents a negative
predictive biomarker of response to ICIs [8]. In order to consolidate antitumor responses, signaling
elicited by these antibodies on T cell subsets need to be better understood; the possible role of
these molecules in regulating Treg function in cancer is an area of growing interest. A large body
of research is now focused on tumor microenvironment (TME) and its influence on cancer growth
and immune evasion mechanisms, which in turn affect responses to immune checkpoint inhibitors.
In that context as well, tumor infiltrating lymphocytes (TIL) (CD4+ and CD8+) are emerging as
potential independent prognostic factors for overall survival (OS) and response rate (RR) regarding ICI
treatment [9,10]. Molecules targeting factors of tumors’ microenvironments, including IDO1 or TLR,
are under investigation. Furthermore, research has shown that commensal microbiota can also affect
ICIs’ responses in a positive or negative manner [11]. This article provides an overview of clinical
impact of immune checkpoint inhibitors on lung cancer management, in light of current knowledge on
immune pathways in terms of biological determinants of sensitivity/resistance and correlates of efficacy.
Table 1. Current and promising prognostic biomarkers in non-small cell lung cancer (NSCLC) treatment.
Prognostic Biomarker Current State of Development
PD-L1 expression FDA-approved and fully implemented in clinical practice
Tumor mutational burden Under investigation
Differential agretopicity index Under investigation
STK11 mutations Under investigation
High levels of tumor infiltrating lymphocytes
(CD4+, CD8+, CD8+/CD4+ ratio) Under investigation
Kynurenine/tryptophan ratios Under investigation
Quinolinic acid concentrations Under investigation
Gut microbiome Under investigation
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Figure 1. Schematic representation of principal interactions targeted by immune checkpoints 
inhibitors, including PD-1 (programmed cell death protein) and PD-L1 (programmed cell death 
ligand 1 protein), CTLA4 (cytotoxic T-lymphocyte antigen 4), B7-1, TCR and MHC (major 
histocompatibility complex) (with the co-function of CD3 and CD8 molecules) pathways, between T-
lymphocytes (T cells) and antigen presenting cells (APCs). 
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expression. Lastly, pembrolizumab, can be employed as a second-line treatment in nonsquamous or 
squamous NSCLC patients with a PD-L1 expression ≥1% [12–20].  
Figure 1. Schematic representation of principal interactions targeted by immune checkpoints inhibitors,
including PD-1 (programmed cell death protein) and PD-L1 (programmed cell death ligand 1 protein),
CTLA4 (cytotoxic T-lymphocyte antigen 4), B7-1, TCR and MHC (major histocompatibility complex)
(with the co-function of CD3 and CD8 molecules) pathways, between T-lymphocytes (T cells) and
antigen presenting cells (APCs).
2. The Clinical Implications of ICIs in Non-Small Cell Lung Cancer (NSCLC)
Since the FDA approval of nivolumab in 2015, immune checkpoint inhibitors have deeply
shaped metastatic and locally advanced NSCLC treatment algorithms. According to ASCO guidelines,
to date, three different drugs are presently FDA approved and recommended in clinical practice
for the treatment of metastatic NSCLC: nivolumab, pembrolizumab and atezolizumab; specifically,
pembrolizumab is recommended for monotherapy, and in the first line setting for patients with
nonsquamous or squamous NSCLC without driver gene mutations (EGFR/ALK) and with a high PD-L1
expression (tumor proportion score (TPS) ≥ 50%). Nivolumab or atezolizumab are recommended
in a second-line setting for nonsquamous or squamous NSCLCs regardless of PD-L1 expression.
Lastly, pembrolizu ab, can be employed as a second-line treatment in nonsquamous or squamous
NSCLC patients with a PD-L1 expression ≥1% [12–20].
Regarding locally advanced NSCLC, durvalumab currently represents the only FDA approved
and recommended ICI for the treatment of unresectable stage III NSCLC patients, irrespective
of histological type and PD-L1 expression, whose disease has not progress d after a previous
chemoradiotherapy treatment [21]. All four of these ICISs exert their activity by blocking either
PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab and durvalumab), interfering with
and partially preventing tumor cells’ immune-escape, thus enhancing patients’ immune surveillance
and T-cell-mediated responses to cancer cells [22–24]. A promising line of research in the treatment of
metastatic NSCLC is exploring chemo-immunotherapy combination therapies, which may represent
a potential standard-of-care therapy, replacing chemotherapy alone. A series of groundbreaking
trials—although not yet ASCO-recommended—have led to FDA approval for pembrolizumab and
atezolizumab in naive NSCLC patients, irrespective of PD-L1 expression: combined with pemetrexed
+ platinum (nonsquamous histology)/(nab)paclitaxel + carboplatin (squamous histology) and with
(nab)paclitaxel + carboplatin + bevacizumab (nonsquamous histology), respectively [20,25–28] (Table 2).
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Table 2. FDA-approved immune checkpoint inhibitors (ICIs) for the treatment of stage III/IV NSCLC.
ICI Treatment Pivotal Trial Setting Target Population FDA Approval
Nivolumab monotherapy
versus docetaxel CheckMate017
II line after
chemotherapy failure
Stage III-B or IV
Squamous NSCLC March 2015
Nivolumab monotherapy
versus docetaxel CheckMate057
II line after
chemotherapy failure
Stage III-B or IV
Nonsquamous NSCLC October 2015
Pembrolizumab monotherapy
versus platinum- based
chemotherapy
KEYNOTE-024 I line (PD-L1 ≥ 50%)
Stage IV
Nonsquamous and
squamous NSCLC
October 2016
Pembrolizumab monotherapy
versus docetaxel KEYNOTE-010
II line after
chemotherapy failure
(PD-L1 ≥ 1%)
Nonsquamous and
squamous NSCLC October 2016
Atezolizumab monotherapy OAK II line afterchemotherapy failure
Stage III-B or IV
Nonsquamous and
squamous NSCLC
October 2016
Durvalumab monotherapy
versus placebo PACIFIC
Durvalumab after
chemoradiotherapy
Stage III unresectable
Nonsquamous and
squamous NSCLC
February 2018
Pembrolizumab +
cis/carboplatin + pemetrexed KEYNOTE-189 I line Nonsquamous NSCLC August 2018
Pembrolizumab +
paclitaxel/nab-paclitaxel +
carboplatin
KEYNOTE-407 I line Stage IV SquamousNSCLC October 2018
Atezolizumab + carboplatin +
paclitaxel + bevacizumab IMpower 150 I line
Stage IV or recurrent
metastatic
Nonsquamous NSCLC
December 2018
ALK: anaplastic lymphoma kinase; CNS: central nervous system; ECOG PS: Eastern Cooperative Oncology Group
Performance Status; EGFR: epidermal growth factor receptor; ICI: immune checkpoint inhibitor; NR: not reached;
NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression free survival; TKI: tyrosine kinase inhibitor.
3. ICIs and Special Populations: Oncogene-Addicted Patients
One key exclusion criterion in first-line treatments with immune checkpoint inhibitors, both as
single agent treatments and as combination therapies, has been represented by the expression of driver
gene mutations (EGFR/ALK). Indeed, most subgroup analyses intending to show a survival benefit
favoring ICI treatment over standard chemotherapy in tirosyne kinase inhibitor (TKI)-pretreated
patients, has failed to meet that endpoint [29–31]. The scientific rationale underlying these results
may be represented by the lower PD-L1 expression and lower mutational burden expressed in
oncogene-addicted patients [29]. Consequently, in oncogene addicted patients, the tumor growth may be
sustained within an uninflamed tumor microenvironment with weak immunogenicity. Dong et al. [32]
analyzed 255 resected NSCLC samples, documenting a significantly higher proportion of strongly
positive PD-L1 expression within the EGFR wild-type group than in the mutated patients. Furthermore,
a decreased mutation burden, lack of T-cell infiltration and reduction in proportion of PD-L1+/CD8+
TILs was observed in EGFR mutated samples. However, things could be about to change as a result
of interesting data from some recent trials. In cohort 1 of the ATLANTIC (advanced non-small-cell
lung cancer) study, a single arm phase II trial—111 EGFR+/ALK+ NSCLC-affected patients with
≥25% (74 patients) or <25% (37 patients) PD-L1 expression progressing after at least two previous
lines of treatment (but ICIS-treatment naive) received durvalumab, an anti-PD-L1 antibody, for up
to one year; as a result, in 12.2% of patients with ≥25% PD-L1 expression, an objective response was
noted, as were favorable safety and tolerability profiles [33]. More importantly, with reference to the
above-mentioned IMpower150 study, a protocol amendment was added to its original design in order
to include EGFR+/ALK+ NSCLC-affected patients; remarkably, in that subgroup of patients as well,
results managed to be consistent with those of the intention-to-treat population. In fact, once again,
results favored the four-drugs arm, including atezolizumab, over the standard one (carboplatin +
paclitaxel + bevacizumab), granting a median progression-free survival (mPFS) of 9.7 months compared
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to 6.1 months (hazard ratio (HR): 0.59) [28]. Based on those results, atezolizumab has been approved
for patients who develop resistance to specific TKIs [34]. Phase I trials documented a reasonable
safety profile when ICIs were combined with EGFR a mutation directed TKI [35–37]. Several clinical
trials investigating the combination of a TKI with an ICI are currently recruiting (e.g., NCT02364609,
NCT01454102 and NCT01998126).
4. Current Biomarkers in Immune Checkpoints Inhibitors
4.1. PD-L1 Expression and TMB
In order to correctly administer immunotherapy, the National Comprehensive Cancer Network
(NCCN) and the College of American Pathologists (CAP), the International Association for the Study
of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) guidelines strongly
recommended that the expression of PD-L1 protein should be tested in patients [38,39]. As a result of the
phase III KEYNOTE-024 clinical trial, the monoclonal human IgG4 antibody, pembrolizumab, directed
against PD-1, has to be considered the first line treatment choice in advanced NSCLC patients with
an expression of PD-L1 in tumor cells (tumor proportion score, TPS) ≥50% [40]. However, the actual
relevance of the levels of PDL-1 expression in tumor samples as indicators of ICIs’ responses is
under debate.
Recent evidence from the phase III KEYNOTE-042 trial strongly encourages the adoption of
pembroluzimab as an alternative to platinum-based therapy, even in cases with low PD-L1 (≥1%)
expression. To date, in addition to pembrolizumab, other drugs, such as nivolumab (anti-PD-1),
and anti-PD-L1 atezolizumab and durvalumab (anti-PD-L1), are clinically available; for each
different drug there is a related anti PD-L1 antibody clone for the immunohistochemistry (IHC) or
immunocytochemistry (ICC) evaluation of TPS. In particular, the 22C3 clone (Dako, Carpinteria,
CA, USA) was used for pembrolizumab treatment choice, whereas the clones 28-8 (Dako),
SP142 (Ventana, Tucson, AZ, USA) and SP263 (Ventana) were related to the administration of
nivolumab, atezolizumab and durvalumab, respectively [41]. The 22C3 clone (Dako) associated with
pembrolizumab has been the only test approved by Food and Drug Administration as a “companion
diagnostic” [42]. Due to the large number of assays and immunostaining platforms available, several
efforts were made in order to harmonize and standardize the results obtained in the TPS evaluation.
In particular, the Blueprint project showed a high concordance rate in TPSs for three (22C3, 28-8 and
SP263) out of four clones [41]. These results were confirmed in the second phase of the Blueprint project
performed on routine clinical samples [43]. Potential limitations in the adoption of PD-L1 as a universal
biomarker for immunotherapy response were represented by: (i) a constitutive expression of PD-L1
in tumor cells without evidence of a pre-stimulation by the immune cells; (ii) the heterogeneity of
the different assays’ performances, the subjective interpretation performed by pathologists of TPSs
and relative thresholds adopted, which may all lead to false positive or negative results; and (iii) the
assessment of tumor infiltrating lymphocytes (TILs). [44] Taking into account the data coming from
nivolumab (CheckMate 017 and Checkmate 057), pembrolizumab (KEYNOTE-010 and KEYNOTE-024),
atezolizumab (OAK) and durvalumab (PACIFIC) pivotal trials, it clearly appears that PD-L1 must be
considered as only a prognostic and not a predictive marker.
Another potentially important marker of response to ICIs has been identified in the tumor
mutational burden (TMB). High TMB represents the presence within the tumor of a high number of
non-synonymous genomic alterations, an expression of a genomic instability, with the potential to
generate several neoantigens [45]. As shown by Rizvi et al., NSCLC patients with high TMBs, treated
with pembrolizumab, showed higher objective responses (ORs) and progression-free survival (PFS),
than those with low TMBs [46]. In addition, in the CHECKMATE-227 clinical trial, the association
of two different immunodrugs (nivolumab plus ipilimumab) showed a similar improvement in PFS
in NSCLC patients with at least 10 mutations per megabase [47] when compared to standard-of care
chemotherapy; these results were irrespective of PD-L1 expression levels: ORR—45.3% versus 26.9%;
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mPFS—7.2 months versus 5.5 months; HR for disease progression or death—0.58 (p < 0.001). However,
following a request by the EMA-CHMP (European Medicines Agency’s Committee for Medicinal
Products for Human Use) and by the FDA about the OS analyses of that study, with reference to
both the high-TMB and the low-TMB (<10 mutations per megabase) subgroups of patients, not only
were the HRs for OS with nivolumab + ipilimumab versus chemotherapy comparable between the
two subgroups (0.77 and 0.78, respectively), but the mOS data also favored nivolumab + ipilimumab
over standard-of-care chemotherapy in both these subsets of patients (23.03 months versus 16.72 months
and 16.20 months versus 12.42, respectively). More extensive studies are required to define the role of
TMB as a prognostic biomarker [48]. An important limitation for testing TMB in clinical practice is
represented by the requirement of a large tissue specimen availability for analysis. Recently, several
studies have evaluated the possibility of adopting the so called “liquid biopsy” for the evaluation
of blood-based TMB (bTMB), with the adoption of a highly sensitive approach in next generation
sequencing (NGS). This approach showed a potential clinical benefit in NSCLC patients treated with
anti–PD-1 and anti–PD-L1 drugs, but further investigations are needed. [49–51]
4.2. Neoantigens
Neoantigens are antigens generated from wild-type antigens due to somatic mutations, that can
be recognized by the patients’ T cells via class I major histocompatibility complex (MHC I), but with
a higher binding affinity when compared to the wild-type antigen/MHC I binding, apparently due to
their enhanced immunogenicity [45]. In a recent trial, extrapolating data from the Cancer Genome
Atlas, Ghorani and colleagues investigated whether the different binding affinities between wild-type
and mutated antigens—also known as the differential agretopicity index or DAI—may represent
a statistically significant prognostic response biomarker in stage III/IV NSCLC or melanoma affected
patients. As a result, data regarding NSCLC patients showed thata low mean DAI was linked to worse
OS (p= 0.004), in contrast to neoantigen mean DAI and neoantigen load, that were associated with
improved OS (p= 0.04 and p = 0.023, respectively); interesting results for sure, but more studies and
more patients will be needed to better interpret these data [52].
4.3. STK11 Mutations
Another interesting prognostic biomarker may be represented by STK11 (serine/threonine kinase
11), one of the most mutated tumor-suppressor genes in NSCLC, that seems to be frequently associated
with KRAS mutations. For example, in a recent retrospective analysis, including 302 stage III/IV
NSCLC-affected patients, 25 of which were STK11-mutated, 13 out of the 25 presented a KRAS
co-mutation (52%, p = 0.0008). Furthermore, although no significant correlation to a worse OS or
PFS was found in STK11-mutated patients, a trend towards worse OS was noted in STK11/KRAS
co-mutated patients [53]. A recent investigation not only confirmed the STK11/KRAS association,
but also demonstrated that an STK11/KRAS co-mutation was associated with lower RR to ICI treatment
and shorter OS and PFS (p < 0.001, p < 0.001 and p = 0.0015, respectively), suggesting the importance of
assessing its potentially negative prognostic role in this subset of patients in further prospective trials [8].
Similar conclusions have been reported in another retrospective study evaluating 567 NSCLC-affected
patients [54]. More recently, in non-squamous NSCLC treated with a combination of platinum,
pemetrexed and pembrolizumab, the STK11/LKB1 genomic alterations were associated with shorter
PFS (mPFS 4.8 m versus 7.2 m, HR 1.5, 95% CI 1.1 to 2.0; p = 0.0063) and shorter OS (mOS 10.6 m
versus 16.7 m, HR 1.58, 95% CI 1.09 to 2.27; p = 0.0083) compared with STK11/LKB1-wild type
tumors [55]. Similar results emerged from a genomic study which documented that, in advanced
NSCLC, the absence of mutation in STK11, TP53 and KEAP1 was associated with longer OS [56].
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5. TME-Associated Biomarkers
5.1. TILs
High levels of tumor infiltrating lymphocytes (CD4+ and CD8+) should be considered, in
NSCLC, as an independent positive prognostic factor for OS and for higher RR to ICI treatment [57].
Accordingly, one of the most recent trials on this topic involving a cohort of 26 NSCLC patients reported
that patients whose tumors had a CD8+ lymphocyte count under 886/mm2 showed low RR to ICIs
treatment (16.7%, p = 0.046), while patients whose tumors had a CD8+ lymphocyte count between
886 and 1899/mm2 exhibited a high RR (60%, p = 0.017), and NSCLC patients harboring CD8+/CD4+
ratios lower than 2 had a low RR (13.3%), when compared to those harboring ratios higher than 2
(RR ranging between 43% and 50% (p = 0.035)). To date, however, further validation for this marker is
still required [58].
5.2. IDO1
IDO1 (indoleamine 2,3-dioxygenases) is a tryptophan-catabolic enzyme, responsible for catalyzing
the conversion of tryptophan into kynurenine, contributing to immune tolerability, due to the
immunosuppressive activity of tryptophan metabolites: T-effectors and NK cells’ functions are
blockaded, and Treg, DC and myeloid-derived suppressor cells (MDSC) activities are enhanced [45,59];
however, IDO1 can also be overexpressed in different cancers, NSCLC included, contributing to the
immunosuppressive TME [60,61]. In an interesting trial, Botticelli et coll. evaluated the association
between IDO1 activity and resistance to ICI treatment, taking into account data from 26 NSCLC patients
and assessing the kynurenine/tryptophan ratio as a possible prognostic biomarker and a surrogate
for IDO1 activity. They reported a statistically significant correlation between early PD (<3 months),
and higher kynurenine/tryptophan ratios and quinolinic acid concentrations (respectively, p= 0.017
and p= 0.005), while conversely noting that patients with lower kynurenine/tryptophan ratios and
quinolinic acid concentrations exhibited better PFS and OS (respectively p= 0.018 and p = 0.0005).
Future, larger studies may shed further light on the role of TME and IDO1 and feasibility of the
kynurenine/tryptophan ratio and feasibility of the kynurenine/tryptophan ratio as a prognostic marker
with respect to ICI treatment [62].
5.3. The Impact of the Microbiome on Responses to ICIs
Metagenomic data has hypothesized that the gut microbiome modulates the tumor responses to
both chemotherapy and immunotherapy, potentially representing a biomarker for patients treated with
ICIs. The gut microbiome retains the potential to interfere with innate and adaptive immune responses
through different mechanisms. Firstly, in patients treated with CTLA-4 and PD1/PD-L1 blockade, the
CD11b+ dendritic cells’ mobilization of the lamina propria, induced by the gut microbiome, enhances
the Th-1 response against Bacteroides fragilis’ capsular polysaccharides [63]. Furthermore, the loss
of microbial diversity limits the antigen presentation, enhancing effector T cells’ functioning in the
periphery and the tumor microenvironment (TME) [64]. Different microbiome clusters have been
identified in responder and non-responder melanoma patients treated with anti-PD1 or CTLA4 MoAbs.
Interestingly, the mice inoculated by fecal transplantation with microbes of the responder patients
resulted in enhanced levels of SIY-specific CD8+ T cells but not of FoxP3+CD4+ regulatory T cells. [65]
The heterogeneity of microbial species’ distribution in relation to country of origin, host diet and
lifestyle means those promising data are not uniform and should be interpreted in relation to the broad
variability that exists [66].
6. Expanding the Landscape: Tumor Microenvironment and T-reg Modulation in NSCLC
Cancerogenesis
The TME is crucial for the growth of cancer cells. In the lung, the TME consists of stromal cells,
fibroblasts, extracellular matrix, endothelial cells and immune cells—like myeloid-derived suppressor
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cells (MDSCs), tumor associated macrophages (TAM), dendritic cells (DC), mast Cells (MC) and
different subtypes of lymphocytes [67]. These cells may often act like “the fuel that feeds the flame” for
a tumor’s growth [67,68]. As a consequence, the immune system might not be able to mount an efficient
response against the antigenic landscape of a tumor itself, thus, be unable to prime an efficient immune
response, per se. Well recognized mechanisms adopted for immune-escape include: (1) a lack of
proper presentation of tumor associated antigens (TAA); (2) immune-suppression achieved through the
secretion of immunosuppressive cytokines and chemokines by TME cells inducing the polarization of
T cell lymphocytes lacking antitumor efficacy, or impairing T cell recruitment in the tumor; (3) recruiting
cells of immune system that downregulate immune responses; (4) mechanisms of immune editing due
to tumor mutations giving rise to epitopes that are not recognized by immune system [2]. The latter
mechanism is a paradoxical effect of the immune response that “selects” tumor clones bearing mutations
not recognized by immune system, thus evading the response [69]. Indeed, T cells may differentiate
into distinct T helper subsets. Cytotoxic T cells and Th1 cells are well known to be able to eliminate
cancer cells, although the anti-tumor effect of these subsets may be severely impaired by a TME and
the expression of inhibitory molecules on cell surfaces. Other T cell subsets, including Th2, Th17 and T
regulatory cells, may have ambivalent roles in cancer [2,70]. In that scenario, T regulatory cells (Treg)
play a crucial role [71].
Due to the peculiar role of Tregs in the down regulation of immune responses, we should address
the possible role of these molecules as targets to regulate Treg function in cancer. In recent years,
much effort has been devoted towards counteracting the expression of inhibitory molecules, such as
anti-CTLA-4 and PD-1, on T cell surfaces. However, despite such efforts, the rate of responses to these
therapies in cancer patients is still far from being satisfactory. CTLA4 and CD28 compete for the same
ligand and deliver opposite effects. Indeed, on the effector T cells, the binding of CTLA4 mediates
inhibitory functions while binding to CD28 triggers T cell activation [72,73].
Treg cells, differing from effector T cells, constitutively express CTLA-4, and that contributes to
their suppressive function. Although the depletion of Tregs through the binding of CTLA4 has been
thought to be a main mechanism of action of such an antibody in immunotherapy, several lines of
evidence show that there is no change of Treg number in tumors upon immunotherapy with antiCTLA4,
despite the efficacy of the treatment [74]. Therefore, it is likely that the major effect of the antiCTLA4
therapy is the impairment of Treg activation, following CTLA4 engagement. As a consequence,
the impairment of T cell functions leads to the reactivation of antitumor T cell responses previously
downregulated by Treg activity. Treg cells preferentially bind to activating costimulatory molecules,
inducing their downregulation on APC surface, thus contributing to reducing the activation of effector
T cells [75–77]. Once activated, CTLA-4 can inhibit cell stimulation through different mechanisms;
besides the competition with CD28 for binding to B7.1/B7.2, signaling through CTLA4 can also inhibit
IL-2 mRNA production or promote the expression of molecules associated to cell cycle arrest or inhibit
the nuclear factors factor κB (NF-κB), nuclear factor of activated T cells (NF-AT) and activator protein 1
(AP-1) [72,75]. In Treg cells, CTLA-4 seems to be associated with the upregulation of FoxP3; indeed, the
activation of this marker increases TGF-β production, which in turn promotes FoxP3 expression [73].
This mechanism is also implicated in the conversion of peripheral CD4+CD25− naive T cells to
CD4+CD25+ regulatory T cells, thus enhancing immune suppression [73,78]. PD-1 is known to inhibit
T cells’ proliferation and effector functions and is also expressed on the Treg’s surface. Differing
from effector cells, PD-1 expressed on Tregs contributes towards promoting immune suppression,
stimulating their proliferation. Moreover, the PD-1 ligand, PD-L1, can induce Foxp3 expression [79].
PD-L1 is associated with the inhibition of AKT/mTOR pathways and expanding iTregs [79,80]. Acting
differently from CTLA-4, PD-1 is activated during the effector phase of T cells’ activation; after TCR
stimulation and the binding of PD-1 with PD-L1, the cytoplasmic tail of PD-1 is phosphorylated and
recruits the phosphatases SHP-1 and SHP-2, which dephosphorylate the molecules downstream of
the TCR, such as ZAP-70 and LCK. Within the TME, those mechanisms are associated with cancer
proliferation due to their effects on signaling pathways determining cytokine production, and T effector
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cells’ proliferation and survival [81–83]. Besides PD-1 and CTLA-4, several other inhibitory molecules
expressed on Tregs are candidates to be targeted to improve anticancer therapies. In the last few
years, particular interest has been directed to the IC TIM-3 as a good target for new lung cancer
immunotherapies [84–86]. This molecule plays a key role in the inhibition of Th1 responses and the
expression of cytokines such as TNF and INF-γ. TIM-3+ Treg cells are associated with more aggressive
forms of tumors, producing more IL-10, granzyme and perforin [85,86]. In the absence of TIM-3 ligand
galectin-9, the five tyrosine residues of TIM-3 cytoplasmic tail are phosphorylated and bind HLA-B
associated transcript 3 (Bat-3). In that condition, TIM-3 can also promote effector T cell activity. When
galectin-9 binds to TIM-3 instead, bat-3 is released and promotes inhibitory signals associated with
programmed cell death, the suppression of Th1 and Th17 responses and the induction of tolerance [87].
TIGIT is an ICI expressed on some Treg subsets and intervenes especially in the suppression of Th1
and Th17 lymphocytes. it was found that TIGIT-positive Tregs have a potent immunosuppressive
action and seem to produce higher levels of IL-10 [39,41]. The exact pathway associated with the
inhibitory activity of TIGIT is not completely clear. It is known that it has a cytoplasmic tail containing
an ITIM and an ITT motif and their phosphorylation is correlated to T cell inhibition. When the ligand
CD155 binds to TIGIT, the phosphatase SHIP1, associated with blocking the signal transduction of
PI3K and MAPK pathways, is recruited [88]. TIGIT promotes immune suppression and interferes with
T effector cells’ activation and proliferation, downregulating molecules that compose or regulate the
TCR. It has been widely recognized that the expansion of Tregs in lung cancer correlates with a poor
outcome [89], and, so far, how the available immunotherapy drugs may modulate Treg in cancer has
not been approached. Figure 2 depicts functional effects of MoAb on molecules expressed on surface
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7. Discussion
The identification of novel molecular targets and the manipulation of immunity is expanding
the horizons of lung cancer management [5,81–90]. Despite evidence of durable responses, currently
approved antibodies against the immune regulators CTLA4 and PD-1/PD-L1 in lung cancer are
effective only in subsets of patients, and resistance after an initial response may occur. A better
understanding of the biological determinants of sensitivity and resistance, and correlates of the
efficacy and characterization of the antitumor i mune response, is required. Evolving knowledge on
tumors’ immune microenvironments has the potential to significantly impact clinical management of
lung cancer.
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In this context, analyses of number of and functions of Tregs may be of critical importance;
and a better understanding of how to modulate Treg function and expansion in cancer may be
fundamental to improving immunotherapy in cancer. While several studies have assessed Tregs in
different tumors, we still lack a comprehension of how we may modify Treg functions to improve
immune responses against cancer. Tregs are indeed plastic and may gain effector functions, thus
contributing to anticancer responses rather than promoting tumor growth [90]. Assessing the effects
of immune checkpoint blockades on Tregs should further improve our ability to promote efficient
immune responses in cancer immunotherapy.
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